Biosimilars: Breaking Down Barriers to Patient Access

Biosimilars undergo rigorous FDA testing prior to approval. Unfortunately, many biosimilar medicines are not available to patients even after they have successfully navigated this stringent regulatory process. In fact, although 20+ biosimilars have been approved by the FDA, only nine are currently commercially available. This is a direct result of the patent schemes used by some brand-name pharmaceutical companies to maintain their lucrative product pricing monopolies beyond the period Congress deemed reasonable.



Biosimilars are
SAFE, EFFECTIVE ALTERNATIVE
versions of expensive brand biologic medicines.

Current estimates suggest that biosimilars could save consumers as much as
$54 BILLION
in the next 10 years.

BARRIERS TO ACCESS

In total, brand-name biologic company anti-competitive tactics and perverse market access barriers have cost America's patients nearly $10 billion since 2015. Patients, taxpayers and the overall health care system are bearing the costs.

EDUCATION INCREASES USE

Many patients don't know that biosimilars are priced competitively with their reference product counterparts. They create valuable savings for patients and the U.S. health care system.



LOST SAVINGS AT THE EXPENSE OF PATIENTS

Patients, taxpayers and the health care system are bearing the costs of patent schemes and tactics delaying access to biosimilars. Delayed entry of biosimilars due to patenting has cost the U.S. health care system an astounding

$7.6 BILLION

in lost savings since 2015.

Ending the exploitation of loopholes that delay access to biosimilars will help to provide patients with safe and competitive drug choices.

To learn more about barriers to patient access, view the white paper series Failure to Launch: Part 1 and Part 2.

Biosimilars Council
A Division of AAM

biosimilarscouncil.org

/Biosimscouncil @biosimscouncil